The company’s strategy is focused on the development of oncology products to be made available to cancer patients by immatics in collaboration with strong partners from the life science industry.

In-licensing: immatics seeks in-licensing opportunities for pre-clinical and clinical substances complementing existing activities of the company in the field of active immunotherapy for oncology.

Out-licensing: it is an integral component of the business model of immatics to capitalize on the value proposition of the immatics discovery engine and the short time required for transition of new product candidates from discovery to pre-clinical and clinical testing.

To learn more about partnering opportunities with immatics, please contact:

immatics biotechnologies GmbH
- Business Development Group -
Fraunhoferstraße 18b
82152 Martinsried/Planegg
Germany
 

Dr. Bettina Kipp
Phone: +49/89/309041-0
Fax: +49/89/309041-55